Incyte

49 articles with Incyte

• Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804

  12/30/2020

  - Incyte and Cellenkos will evaluate the combination of ruxolitinib (Jakafi ® ) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis - Incyte has an exclusive option to acquire sole rights to CK0804

• Incyte to Present at Investor Conference

  12/9/2020

  Incyte (Nasdaq:INCY) announced today that it will present at the 39 th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solut

• Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

  12/7/2020

  - Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted for presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020) - Investor conference call and webcast scheduled for today, December 7, at 10:00 a.m. ET (7:00 a.m. PT)

• Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

  12/4/2020

  Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi ® ) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease - Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 - Findings from the study are being presented at ASH 2020, and complement previously-reported positive results for Jakafi in

• Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting

  11/9/2020

  Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually from November 11-14, 2020.

• Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

  11/5/2020

  Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended September 30, 2020; Jakafi ® (ruxolitinib) revenues of $488 million in Q3 2020 (+13% vs Q3 2019); Incyte tightens full year 2020 Jakafi revenue guidance to a range of $1.910 to $1.940 billion Strong momentum behind commercial launches of both Monjuvi ® (tafasitamab-cxix) and Pemazyre ® (pemigatinib) in the U.S.

• Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers

  10/30/2020

  Incyte (Nasdaq:INCY) today announced that the company has again been named a top biopharma employer by Science magazine through its Top Employers Survey of the global pharmaceutical and biotech industry. This year, Incyte ranked second, marking the third consecutive year the c

• Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments

  10/29/2020

  Results reinforce that ruxolitinib cream treatment results in a rapid, substantial and sustained reduction in itch - Results also demonstrate improvement in patient-reported perceptions of sleep quality, sleep depth and restoration associated with sleep as measured by the PROMIS ® Short Form-Sleep Disturbance (8b) questionnaire - Oral presentation will be available on-demand as part of the 29th EADV Virtual Congress

• Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

  9/17/2020

  Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the companies intend to host a conference call and webcast to discuss global development, unmet need and commercial opportunities for tafasitamab.

• Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community

  9/9/2020

  Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community.

• Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

  9/2/2020

  — Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) — Tabrecta is the fourth molecule discovered by Incyte scientists to be approved by the FDA — Novartis has exclusive worldwide development and commercialization rights to Tabrecta WILMINGTON, Del.--( BUSINESS WIRE )-- Incyte (Nasdaq: INCY) today ann

• Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

  7/23/2020

  - Jakafi® demonstrated superior overall response rate in patients with steroid-refractory chronic graft-versus-host disease at Week 24 compared to best available therapy

• Incyte Investor Conference Update

  6/17/2020

  Incyte (Nasdaq:INCY) has updated its presentation time at the following investor conference: JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT). The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged. The presentations for both conferences will be webcast

• Incyte Launches New Global Responsibility Section on Incyte.com

  6/15/2020

  Incyte (Nasdaq:INCY) today announced that a new Global Responsibility section has been launched as part of Incyte.com.

• Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab

  5/20/2020

  Incyte (NASDAQ:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody.

• MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

  5/18/2020

  MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today reported updated results from the ongoing Phase 2 L-MIND study investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

• Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings

  5/14/2020

  Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14).

• Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease

  4/22/2020

  Incyte (Nasdaq:INCY) today announced that data from the Phase 3 REACH2 study have been published in The New England Journal of Medicine demonstrating that ruxolitinib (Jakafi®) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT).

• Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

  4/2/2020

  Incyte (Nasdaq:INCY) today announced the Company is working with the U.S. Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib (Jakafi®) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm.

• Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community

  2/19/2020

  Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community.